Screener
Gyre Therapeutics, Inc. GYRE Gyre Pharmaceuticals — Allocated Share Based Compensation Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
FAQ
- What is Gyre Therapeutics, Inc.'s gyre pharmaceuticals — allocated share based compensation expense?
- Gyre Therapeutics, Inc. (GYRE) reported gyre pharmaceuticals — allocated share based compensation expense of $1.21M in Q2 2026.
- How has Gyre Therapeutics, Inc.'s gyre pharmaceuticals — allocated share based compensation expense changed year-over-year?
- Gyre Therapeutics, Inc.'s gyre pharmaceuticals — allocated share based compensation expense increased by 245.6% year-over-year, from $349K to $1.21M.
- What does gyre pharmaceuticals — allocated share based compensation expense mean?
- This represents the portion of total share-based compensation costs assigned to the specific business segment. It reflects the non-cash expense associated with equity-based awards granted to employees within that segment. Monitoring this helps assess the true cost of human capital and the impact of equity incentives on segment margins.
Ask your AI about Gyre Therapeutics, Inc.'s gyre pharmaceuticals — allocated share based compensation expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude